Tetra Therapeutics

"Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Alzheimer’s disease, Fragile X Syndrome, traumatic brain injury, and other brain disorders."

"Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4), an enzyme family that plays key roles in memory formation, learning, neuroinflammation, and traumatic brain injury. Tetra Therapeutics is headquartered in Grand Rapids, Michigan."

Latest Tetra Therapeutics News & Features

BRIEF—Shionogi's zatolmilast gets FDA Rare Pediatric disease designation

29 September 2023

Positive Phase II Study of BPN14770 in patients with Fragile X syndrome

2 November 2020

Tetra to become a wholly-owned subsidiary of Shionogi

26 May 2020

Fragile X race hots up as Shionogi ups stake in Tetra

6 March 2020

Tetra Therapeutics

Latest Tetra Therapeutics News & Features

Today's issue